The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Trabectedin: A Review of its Use in the Management of Soft Tissue Sarcoma and Ovarian Cancer
Abstract
Trabectedin (Yondelis); ET-743) is an antineoplastic agent that was originally derived from the Caribbean marine tunicate Ecteinascidia turbinata and is now produced synthetically. It binds to the minor groove of DNA, disrupting the cell cycle and inhibiting cell proliferation. Intravenous trabectedin administered once every 3 weeks is approved as monotherapy in Europe for use in patients with advanced soft tissue sarcoma (STS) after failure of standard therapy with anthracyclines or ifosfamide, or who are unsuited to receive these agents. It also has orphan drug status in STS in the US and in ovarian cancer in the US and Europe, and is under investigation as combination therapy in patients with recurrent ovarian cancer. In clinical trials, trabectedin showed efficacy in the treatment of patients with advanced or metastatic STS, especially those with leiomyosarcoma or liposarcoma, as well as in women with platinum-sensitive advanced or recurrent ovarian cancer. In addition, its tolerability profile was generally manageable. The introduction of trabectedin expands the currently limited range of effective treatment options for patients with advanced or metastatic STS; trabectedin also has the potential to be a beneficial treatment for advanced or recurrent ovarian cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It was claimed to block the substantial DNA and transcription interacting effect as the chemical structure binds to the minor groove of DNA covalently and interact with transcription factors (e.g., SP-1) directly [223].”
From Marine Natural Products: A Source of Novel Anticancer Drugs (2019) · cites this paper as [223]
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B. N., Wenzel, L. B., Huang, H. Q., Baergen, R. N., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,626
Parmar, M., Ledermann, J. A., Colombo, N., du Bois, A., Jf, D., Kristensen, G. B., Wheeler, S., Swart, A. M., Qian, W., Torri, V., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13718-x · Cited by 1,180
Soft-Tissue Sarcomas in Adults
Clark, M. A., Fisher, C., Judson, I. R., & Thomas, J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041866 · Cited by 910
Cormier, J. N., & Pollock, R. E. (2004) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.2.94 · Cited by 861
Marine natural products as anticancer drugs
Simmons, T. L., Andrianasolo, E., McPhail, K., Flatt, P., & Gerwick, W. H. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.333.4.2 · Cited by 597
Grosso, F., Jones, R. L., Demetri, G. D., Judson, I. R., Blay, J., Cesne, A. L., Sanfilippo, R. G., Casieri, P., Collini, P., Dileo, P., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70175-4 · Cited by 490
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
Glabbeke, M. M. V., Verweij, J., Judson, I. R., & Nielsen, O. S. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00398-7 · Cited by 462
Cesne, A. L., Blay, J., Judson, I. R., van Oosterom, A., Verweij, J., Radford, J. A., Lorigan, P. C., Rodenhuis, S., Ray-Coquard, I., Bonvalot, S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.180 · Cited by 458
Research works printed but not linked: 8
- Aletti, 2007, Mayo Clin Proc, 82, 751, 10.1016/S0025-6196(11)61196-8 · DOI
- Friedman, 2002, Cancer Res, 62, 3377
- Scotlandi, 2002, Clin Cancer Res, 8, 3893
- Li, 2001, Clin Cancer Res, 7, 2908
- Takahashi, 2001, Clin Cancer Res, 7, 3251
- Manara, 2005, Int J Oncol, 27, 1605
- Donald, 2003, Cancer Res, 63, 5902
- van Kesteren, 2000, Clin Cancer Res, 6, 4725
Cited by
Sorted by citations
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,086
Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
Lordan, S., Ross, R. P., & Stanton, C. (2011) · Marine Drugs · doi:10.3390/md9061056 · Cited by 779
Marine Natural Products: A Source of Novel Anticancer Drugs
Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555
Demetri, G. D., Chawla, S. P., von Mehren, M., Ritch, P. S., Baker, L. H., Blay, J., Hande, K. R., Keohan, M. L., Samuels, B. L., Schuetze, S. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0088 · Cited by 537
Metadata
- Authors
- Carter, N. J., & Keam, S. J.
- Affiliations
- Wolters Kluwer Health (NZ)
- Corresponding author
- Carter, Natalie J
- ORCID
- Keam, Susan J
- Venue
- Drugs
- Published
- 2007
- Volume
- 67
- Issue
- 15
- Pages
- 2257-2276
- ISSN
- 0012-6667 (ISSN-L)
- OpenAlex
- W1981744051
- Cited by
- 107
- References
- 57
- Citations by year
- 2025: 3 · 2024: 5 · 2023: 2 · 2022: 11 · 2021: 4 · 2020: 4 · 2019: 5 · 2018: 1 · 2017: 1 · 2016: 5 · 2015: 4 · 2014: 4 · 2013: 3 · 2012: 4
- FWCI
- 10.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and pharmacology of benzodiazepine derivatives
- Keywords
- trabectedin, Ecteinascidia turbinata, marine natural products, soft tissue sarcoma, ovarian cancer, DNA minor groove binding, nucleotide excision repair, G2/M cell cycle arrest, drug resistance, pharmacokinetics, pharmacodynamics, combination chemotherapy, liposarcoma, leiomyosarcoma, platinum-sensitive ovarian cancer
- MeSH terms
- Trabectedin, Animals, Dioxoles, Female, Humans, Ovarian Neoplasms, Sarcoma, Randomized Controlled Trials as Topic, Antineoplastic Agents, Alkylating, Tetrahydroisoquinolines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
